Lacidipin Belupo (Lacidipine)

Lacidipine blocks L-type calcium channels in the smooth muscle of blood vessels. By preventing calcium entry, it causes the vessels to relax and widen, decreasing peripheral resistance and ultimately lowering systemic blood pressure.

The exact dose of lacidipine is determined by the prescribing healthcare professional based on the patient’s condition, response, and any co‑existing medical issues. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for lacidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Lacidipin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacidipin belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes vasodilation. Compared with ACE inhibitors or beta‑blockers, it may have a lower incidence of cough but can cause more peripheral edema. Choice of therapy depends on patient profile and comorbidities.

Lacidipin tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Lacidipin is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, myocardial infarction, hepatic dysfunction, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, chest pain, severe liver symptoms, or swelling of the face or throat.

Lacidipin is contraindicated in patients with known hypersensitivity to lacidipine or any component of the formulation, and it should be used with caution in individuals with severe liver disease, unstable angina, or those taking strong CYP3A4 inhibitors.